Halozyme’s Spotlight Shifts To Enhanze Exclusively After PEGPH20 Fails In Phase III

 
• By Mandy Jackson

The Enhanze drug delivery technology, which is expected to be profitable starting next year, takes center stage as Halozyme discontinues PEGPH20 development and cuts its oncology operations along with 160 jobs.

SC1911_Spotlight_76770868_1200.jpg
After 160 job cuts and with an Enhanze-only focus, Halozyme will be profitable next year. • Source: Shutterstock

More from Strategy

More from Business